In May of 2009,
StemCell Pharma, Inc. (SCPI) will organize an international
commission for the examination of Edi Leanca, a Romanian boy born
blind and diagnosed with Leber’s Congenital Amaurosis (LCA), the most
severe form of Retinitis Pigmentosa (RP), who regained his sight
after receiving stem cell implants. The technique used on Edi Leanca
is a proprietary technique owned by SCPI. The examination will take
place in Bucharest, Romania by a commission made up of retinal
experts with representatives from Romania, the European community,
Russia and the USA. A report will be issued regarding their
examination.
You may find the entire story of Edi Leanca on the SCPI website
stemcellpharmainc.
SCPI is a privately held Nevada corporation formed in May of 2005. It
owns the worldwide rights to two inventions (patents pending) namely:
1. An Amniotic Membrane Stem Cell Telomerase Enhanced Implant and…
2. “The Transsclera Technology for Delivery of Stem Cells plus
Enhancing Factors”
The first invention deals with a proprietary technique, whereby
using telomerase modulators, the number of multiplications of the stem
cells can be manipulated either by keeping them at normal rate or if
needed to increase their multiplication by extending the telomerase
lengths.
The second invention “The Transsclera Technology,” uses the SCPI
formulations (stem cells plus enhancing factors) applied on the
sclera (the white of the eye) where through a proprietary technique,
the formulations cross rapidly the retina layers, landing on the
retinal pigment epithelium (RPE) and the photoreceptors layers. It
is postulated that the stem cells would next, through a process of
differentiation become cones and rods, eventually clean the area of
damaged or dead photoreceptors, construct a new photoreceptor layer
and restore a certain degree of vision.
Based upon this technology, SCPI had developed blue prints that would
allow through setting up, licensing or joint venture (JV) agreements
to set up new stem cell clinics or with existing stem cell clinics
abroad.
Another project this time in the US would involve setting up an
experimental stem cell clinic authorized in Nevada. This project if
and when approved won’t be the first one successfully concluded. In
July of 1977, the Governor of Nevada Mike O’Callaghan signed the bill
H.R. 54 authorizing the manufacturing and marketing in Nevada of
Gerovital H3, GH3, the Romanian anti-aging drug brought to the US by
Dr. Sapse. Gerovital H3 is now used all over the US.
SCPI has also available two stem cell treatments in injectable form
containing formulations intended for retinal diseases and for the
treatment of aging and diseases associated with aging.
These products are intended for clinical trials FDA type, in the US
or abroad, and when or if approved for marketing, they would become
available to patients via medical prescriptions issued by treating
physicians. (Dr. Sapse President of StemCell Pharma, Inc. had
received US patents for the treatment of Alzheimer’s and depression
in an aging population.)
StemCell Pharma, Inc.